Regenerating islet-derived 3-alpha is a biomarker of gastrointestinal graft-versus-host disease

James L M Ferrara, Andrew C. Harris, Joel K. Greenson, Thomas M. Braun, Ernst Holler, Takanori Teshima, John E. Levine, Sung W J Choi, Elisabeth Huber, Karin Landfried, Koichi Akashi, Mark Vander Lugt, Pavan Reddy, Alice Chin, Qing Zhang, Samir Hanash, Sophie Paczesny

Research output: Contribution to journalArticle

154 Citations (Scopus)

Abstract

There are no plasma biomarkers specific for GVHD of the gastrointestinal (GI) tract, the GVHD target organ most associated with nonrelapse mortality (NRM) following hematopoietic cell transplantation (HCT). Using an unbiased, large-scale, quantitative proteomic discovery approach to identify candidate biomarkers that were increased in plasma from HCT patients with GI GVHD, 74 proteins were increased at least 2-fold; 5 were of GI origin. We validated the lead candidate, REG3α, by ELISA in samples from 1014 HCT patients from 3 transplantation centers. Plasma REG3α concentrations were 3-fold higher in patients at GI GVHD onset than in all other patients and correlated most closely with lower GI GVHD. REG3α concentrations at GVHD onset predicted response to therapy at 4 weeks, 1-year NRM, and 1-year survival (P ≤ .001). In a multivariate analysis, advanced clinical stage, severe histologic damage, and high REG3α concentrations at GVHD diagnosis independently predicted 1-year NRM, which progressively increased with higher numbers of onset risk factors present: 25% for patients with 0 risk factors to 86% with 3 risk factors present (P <.001). REG3α is a plasma biomarker of GI GVHD that can be combined with clinical stage and histologic grade to improve risk stratification of patients.

Original languageEnglish (US)
Pages (from-to)6702-6708
Number of pages7
JournalBlood
Volume118
Issue number25
DOIs
StatePublished - Dec 15 2011
Externally publishedYes

Fingerprint

Biomarkers
Graft vs Host Disease
Grafts
Plasmas
Cell Transplantation
Mortality
Plasma Cells
Proteomics
Gastrointestinal Tract
Multivariate Analysis
Transplantation
Enzyme-Linked Immunosorbent Assay
Proteins
Survival

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Ferrara, J. L. M., Harris, A. C., Greenson, J. K., Braun, T. M., Holler, E., Teshima, T., ... Paczesny, S. (2011). Regenerating islet-derived 3-alpha is a biomarker of gastrointestinal graft-versus-host disease. Blood, 118(25), 6702-6708. https://doi.org/10.1182/blood-2011-08-375006

Regenerating islet-derived 3-alpha is a biomarker of gastrointestinal graft-versus-host disease. / Ferrara, James L M; Harris, Andrew C.; Greenson, Joel K.; Braun, Thomas M.; Holler, Ernst; Teshima, Takanori; Levine, John E.; Choi, Sung W J; Huber, Elisabeth; Landfried, Karin; Akashi, Koichi; Vander Lugt, Mark; Reddy, Pavan; Chin, Alice; Zhang, Qing; Hanash, Samir; Paczesny, Sophie.

In: Blood, Vol. 118, No. 25, 15.12.2011, p. 6702-6708.

Research output: Contribution to journalArticle

Ferrara, JLM, Harris, AC, Greenson, JK, Braun, TM, Holler, E, Teshima, T, Levine, JE, Choi, SWJ, Huber, E, Landfried, K, Akashi, K, Vander Lugt, M, Reddy, P, Chin, A, Zhang, Q, Hanash, S & Paczesny, S 2011, 'Regenerating islet-derived 3-alpha is a biomarker of gastrointestinal graft-versus-host disease', Blood, vol. 118, no. 25, pp. 6702-6708. https://doi.org/10.1182/blood-2011-08-375006
Ferrara JLM, Harris AC, Greenson JK, Braun TM, Holler E, Teshima T et al. Regenerating islet-derived 3-alpha is a biomarker of gastrointestinal graft-versus-host disease. Blood. 2011 Dec 15;118(25):6702-6708. https://doi.org/10.1182/blood-2011-08-375006
Ferrara, James L M ; Harris, Andrew C. ; Greenson, Joel K. ; Braun, Thomas M. ; Holler, Ernst ; Teshima, Takanori ; Levine, John E. ; Choi, Sung W J ; Huber, Elisabeth ; Landfried, Karin ; Akashi, Koichi ; Vander Lugt, Mark ; Reddy, Pavan ; Chin, Alice ; Zhang, Qing ; Hanash, Samir ; Paczesny, Sophie. / Regenerating islet-derived 3-alpha is a biomarker of gastrointestinal graft-versus-host disease. In: Blood. 2011 ; Vol. 118, No. 25. pp. 6702-6708.
@article{0557669c33c24de9adb8c8256b429260,
title = "Regenerating islet-derived 3-alpha is a biomarker of gastrointestinal graft-versus-host disease",
abstract = "There are no plasma biomarkers specific for GVHD of the gastrointestinal (GI) tract, the GVHD target organ most associated with nonrelapse mortality (NRM) following hematopoietic cell transplantation (HCT). Using an unbiased, large-scale, quantitative proteomic discovery approach to identify candidate biomarkers that were increased in plasma from HCT patients with GI GVHD, 74 proteins were increased at least 2-fold; 5 were of GI origin. We validated the lead candidate, REG3α, by ELISA in samples from 1014 HCT patients from 3 transplantation centers. Plasma REG3α concentrations were 3-fold higher in patients at GI GVHD onset than in all other patients and correlated most closely with lower GI GVHD. REG3α concentrations at GVHD onset predicted response to therapy at 4 weeks, 1-year NRM, and 1-year survival (P ≤ .001). In a multivariate analysis, advanced clinical stage, severe histologic damage, and high REG3α concentrations at GVHD diagnosis independently predicted 1-year NRM, which progressively increased with higher numbers of onset risk factors present: 25{\%} for patients with 0 risk factors to 86{\%} with 3 risk factors present (P <.001). REG3α is a plasma biomarker of GI GVHD that can be combined with clinical stage and histologic grade to improve risk stratification of patients.",
author = "Ferrara, {James L M} and Harris, {Andrew C.} and Greenson, {Joel K.} and Braun, {Thomas M.} and Ernst Holler and Takanori Teshima and Levine, {John E.} and Choi, {Sung W J} and Elisabeth Huber and Karin Landfried and Koichi Akashi and {Vander Lugt}, Mark and Pavan Reddy and Alice Chin and Qing Zhang and Samir Hanash and Sophie Paczesny",
year = "2011",
month = "12",
day = "15",
doi = "10.1182/blood-2011-08-375006",
language = "English (US)",
volume = "118",
pages = "6702--6708",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "25",

}

TY - JOUR

T1 - Regenerating islet-derived 3-alpha is a biomarker of gastrointestinal graft-versus-host disease

AU - Ferrara, James L M

AU - Harris, Andrew C.

AU - Greenson, Joel K.

AU - Braun, Thomas M.

AU - Holler, Ernst

AU - Teshima, Takanori

AU - Levine, John E.

AU - Choi, Sung W J

AU - Huber, Elisabeth

AU - Landfried, Karin

AU - Akashi, Koichi

AU - Vander Lugt, Mark

AU - Reddy, Pavan

AU - Chin, Alice

AU - Zhang, Qing

AU - Hanash, Samir

AU - Paczesny, Sophie

PY - 2011/12/15

Y1 - 2011/12/15

N2 - There are no plasma biomarkers specific for GVHD of the gastrointestinal (GI) tract, the GVHD target organ most associated with nonrelapse mortality (NRM) following hematopoietic cell transplantation (HCT). Using an unbiased, large-scale, quantitative proteomic discovery approach to identify candidate biomarkers that were increased in plasma from HCT patients with GI GVHD, 74 proteins were increased at least 2-fold; 5 were of GI origin. We validated the lead candidate, REG3α, by ELISA in samples from 1014 HCT patients from 3 transplantation centers. Plasma REG3α concentrations were 3-fold higher in patients at GI GVHD onset than in all other patients and correlated most closely with lower GI GVHD. REG3α concentrations at GVHD onset predicted response to therapy at 4 weeks, 1-year NRM, and 1-year survival (P ≤ .001). In a multivariate analysis, advanced clinical stage, severe histologic damage, and high REG3α concentrations at GVHD diagnosis independently predicted 1-year NRM, which progressively increased with higher numbers of onset risk factors present: 25% for patients with 0 risk factors to 86% with 3 risk factors present (P <.001). REG3α is a plasma biomarker of GI GVHD that can be combined with clinical stage and histologic grade to improve risk stratification of patients.

AB - There are no plasma biomarkers specific for GVHD of the gastrointestinal (GI) tract, the GVHD target organ most associated with nonrelapse mortality (NRM) following hematopoietic cell transplantation (HCT). Using an unbiased, large-scale, quantitative proteomic discovery approach to identify candidate biomarkers that were increased in plasma from HCT patients with GI GVHD, 74 proteins were increased at least 2-fold; 5 were of GI origin. We validated the lead candidate, REG3α, by ELISA in samples from 1014 HCT patients from 3 transplantation centers. Plasma REG3α concentrations were 3-fold higher in patients at GI GVHD onset than in all other patients and correlated most closely with lower GI GVHD. REG3α concentrations at GVHD onset predicted response to therapy at 4 weeks, 1-year NRM, and 1-year survival (P ≤ .001). In a multivariate analysis, advanced clinical stage, severe histologic damage, and high REG3α concentrations at GVHD diagnosis independently predicted 1-year NRM, which progressively increased with higher numbers of onset risk factors present: 25% for patients with 0 risk factors to 86% with 3 risk factors present (P <.001). REG3α is a plasma biomarker of GI GVHD that can be combined with clinical stage and histologic grade to improve risk stratification of patients.

UR - http://www.scopus.com/inward/record.url?scp=84055177580&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84055177580&partnerID=8YFLogxK

U2 - 10.1182/blood-2011-08-375006

DO - 10.1182/blood-2011-08-375006

M3 - Article

VL - 118

SP - 6702

EP - 6708

JO - Blood

JF - Blood

SN - 0006-4971

IS - 25

ER -